Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion cheers success of anemia therapy
Paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening form of hemolytic anemia, is an acquired genetic blood disorder characterized by destruction of red blood cells by the body's
Paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening form of hemolytic anemia, is an acquired genetic blood disorder characterized by destruction of red blood cells by the body's
In the study patients receiving Aranesp were nearly three times more likely to achieve a hematopoietic response than patients receiving a placebo. “Patients with cancer who are not
Mantle cell lymphoma (MCL) is a relatively uncommon and aggressive form of non-Hodgkin’s lymphoma for which there was no standard of care in the relapsed or refractory setting.
We have a strong pipeline of new products in the FDA, additional new products coming through the development process, such as our troponin assay, but our marketing efforts
DOV said that the drug candidates DOV 21,947 and DOV 216,303, have been terminated by the parties effective December 6, 2006. New Jersey-based DOV said that it will
“From an anti-trust perspective, there are no objections so the transaction can proceed,” said an Actelion spokesman. If the proposed merger is consummated, CoTherix will become an indirect
Orphan drug designation will give the biotech firm European marketing exclusivity for up to 10 years. Orphan status is given to drugs that provide for unmet medical needs
Non steroidal anti-inflammatory drugs such as naproxen and naproxcinod represent the established symptomatic treatment for osteoarthritis. The cardiovascular safety of these drugs has been debated and they are
Researchers suggested the findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients. The UC researchers
Typically, the FDA requires two adequate and well-controlled studies to establish substantial evidence of effectiveness. In September 2006, Acorda said the drug improved the walking speed in significantly